Evidence map›Paper›PMID 21878090›Full record

ArticleBMC pharmacology2011

Towards the development of novel Trypanosoma brucei RNA editing ligase 1 inhibitors.

Jacob D Durrant, J Andrew McCammon

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jacob D DurrantDepartment of Chemistry & Biochemistry, University of California San Diego, La Jolla, California 92093-0365, USA. jdurrant@ucsd.edu
J Andrew McCammon
Center for Theoretical Biological Physics · USUniversity of California, San Diego · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
THEORY OF BIOMOLECULAR DIFFUSIONR01GM031749 · NIGMS · UNIVERSITY OF HOUSTON · PI HUBER, GARY ALEXANDER, MCCAMMON, JAMES ANDREW · 1985 to 2022
$7.8M
Howard Hughes Medical InstituteNIGMS NIH HHS GM31749NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

backgroundTrypanosoma brucei (T. brucei) is an infectious agent for which drug development has been largely neglected. We here use a recently developed computer program called AutoGrow to add interacting molecular fragments to S5, a known inhibitor of the validated T. brucei drug target RNA editing ligase 1, in order to improve its predicted binding affinity.

resultsThe proposed binding modes of the resulting compounds mimic that of ATP, the native substrate, and provide insights into novel protein-ligand interactions that may be exploited in future drug-discovery projects.

conclusionsWe are hopeful that these new predicted inhibitors will aid medicinal chemists in developing novel therapeutics to fight human African trypanosomiasis.

Indexed as

Adenosine TriphosphateAnimalsBinding SitesCarbon-Oxygen LigasesCatalytic DomainCrystallography, X-RayDrug DesignDrug DiscoveryEnzyme InhibitorsHumansMitochondrial ProteinsModels, MolecularMolecular StructureProtein BindingProtein Structure, TertiaryRNA EditingAdenosine TriphosphateCarbon-Oxygen LigasesEnzyme InhibitorsMitochondrial ProteinsREL1 RNA ligase, Trypanosoma brucei

Identifiers

PMID21878090
PMCPMC3196686
OpenAlexW2054208361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.